Shamburg News · 8-K filed Nov 5, 2026, 6:08 AM EST

DataMEDS AI Terminates Second Amended and Restated Letter of Intent With Multiple Parties

MEDS · DataMeds AI, Inc.

  • Material agreement
  • Reg FD disclosure
  • Other event
  • Materiality: medium

On November 3, 2026, DataMEDS AI, Inc. provided written notice terminating its Second Amended and Restated Letter of Intent dated October 19, 2026, with EOS Technology Holdings, Scilex Holding Company, Datavault AI, HealthBridge Advisors, Tollo Health, and REBOOT Health AI, effective immediately. The LOI had contemplated share-based acquisitions of intellectual property, a PharmacyChain license expansion, and a controlling interest in Tollo Health. The company stated it owes no fees as a result and will no longer issue shares under the LOI, while its existing REBOOT and Datavault license agreements remain in effect.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.02, 7.01, 9.01, accession 0001493152-26-050033.

Written from the filing by Shamburg Markets. Figures are as reported by the company.